TürkiyeSGK and reimbursement
Oral migalastat for Fabry disease added to the SGK reimbursement list
Based on a single news source or an institutional announcement. The level of scientific evidence is low; check the details with a doctor.
On January 17, 2026, migalastat, used in Fabry disease, was added to the SGK (Social Security Institution) reimbursement list. Gen İlaç, the company that supplies the drug in Türkiye, announced this on the Public Disclosure Platform (Kamuyu Aydınlatma Platformu). The drug is taken by mouth as a capsule. It is used in patients aged 12 years and older who have a suitable gene change.
What does it mean for patients and families?
The drug is not suitable for every person with Fabry disease; a gene test determines whether it is suitable. You can ask the center where you are followed about the payment conditions.
Source
Paratic: GENIL ilacı SGK geri ödeme listesine alındı!
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Fabry disease
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.